DEF: Pluri Inc. Schedules Annual Shareholder Meeting for June 15, 2026

Pluri Inc. has issued a proxy statement announcing its annual meeting of shareholders to be held on June 15, 2026, to elect directors, ratify auditors, and address other business.

Summary

• Pluri Inc. is holding its annual meeting of shareholders on June 15, 2026, at its offices in Haifa, Israel.
• The meeting's agenda includes the election of five directors, ratification of Kesselman & Kesselman as independent auditors for the fiscal year ending June 30, 2026, and other business.
• Shareholders of record as of April 23, 2026, are entitled to vote.
• Proxy materials are available online, and shareholders are encouraged to vote by internet, telephone, or mail.
• The company has 10,774,666 common shares outstanding as of April 23, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the procedural nature of a proxy statement, but also noting the concerning financial metrics like negative TSR and increasing net loss.

Positives

• The company is holding its annual meeting as scheduled, providing a forum for shareholder engagement and governance.
• The board has nominated experienced individuals for director positions, with a mix of financial, business, and industry expertise.
• The company is seeking to ratify a reputable accounting firm, Kesselman & Kesselman (a member of PricewaterhouseCoopers International Limited), for the upcoming fiscal year, indicating a commitment to financial transparency.
• The company has a clear process for shareholder communication with the Board of Directors.

Negatives

• One director, Mr. Zami Aberman, is not seeking re-nomination, though this is stated not to be due to any disagreement.
• The company experienced a period where its Audit Committee did not comply with Nasdaq Listing Rule 5605(c)(2)(A) requirements for independent directors, though it regained compliance.
• The company's Total Shareholder Return (TSR) has been negative for the past two fiscal years (-$406 for FY24, -$489 for FY25), indicating significant shareholder value erosion.
• The company's net loss increased by 9% from FY24 to FY25, reaching $23.25 million, primarily due to increased G&A expenses and higher financial expenses.

Risks

• The company's financial performance, as indicated by a net loss and negative TSR, presents ongoing financial risks.
• Potential for broker non-votes on non-routine proposals, which could impact voting outcomes if shareholder participation is low.
• The company's reliance on specific executive officers and the potential impact of their departure or changes in their compensation structure.
• The company has experienced salary reductions for its CEO and CFO in recent periods (December 2025 - February 2026) due to financial stability concerns, indicating potential financial strain.

Future Outlook

The filing is a proxy statement for an annual meeting and does not contain specific forward-looking financial guidance. However, the election of directors and ratification of auditors are standard procedures for ongoing operations.

Management Comments

• "We believe that having different persons serving as Chairman and CEO, together with three independent directors is the optimal Board structure to provide independent oversight and management accountability while ensuring that our strategic plans are pursued to optimize long-term shareholder value."
• "The Board thanks Mr. Aberman for his years of service and contributions to the Company."
• "In order to ensure the Companys financial stability, the Board approved, at the recommendation of the Companys management, a 30% reduction in the monthly cash salary of the CFO, applicable to January 2026 and February 2026... and a 20% monthly reduction in director fees, applicable to the months of December 2025 through February 2026."

Industry Context

StockSavvy.ai notes that Pluri Inc.'s proxy statement for its annual meeting is typical for a publicly traded company, focusing on governance and operational continuity. The company operates in the life sciences and medical technology sectors, where robust governance and clear financial oversight are critical for investor confidence, especially given the reported net losses and negative TSR.

Comparison to Industry Standards

• The company's Audit Committee structure and compliance with Nasdaq listing rules are benchmarked against standard requirements for publicly traded companies on Nasdaq.
• The compensation structure for executives, including base salary, bonuses, and equity awards, is presented in a format aligned with SEC regulations (e.g., Summary Compensation Table, Pay Versus Performance Table), which allows for comparison with industry peers.
• The company's net loss of $23.25 million in FY2025, while a concern, needs to be evaluated against the financial performance of other early-stage or development-focused companies in the biotechnology and life sciences sectors, which often experience significant R&D expenses and operating losses before achieving profitability.

Management Changes

Corporate Governance

Related Party Transactions

• Pluri Inc. and its subsidiary Pluri Biotech Ltd. purchased approximately 79% of Kokomodo Ltd. equity from Chutzpah Holdings Ltd. and Plantae Bioscience Ltd. (companies wholly owned or controlled by director Alexandre Weinstein) for $4.5 million, paid in Pluri Inc. Common Shares. A convertible loan of $0.5 million was also transferred.
• Compensation arrangements for directors and executive officers, including salaries, bonuses, and equity awards, are detailed, with some involving related entities or individuals.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification. The company's negative TSR and increasing net loss may impact shareholder confidence and stock value.
• Directors and Management: Subject to compensation adjustments and salary reductions due to financial stability concerns, indicating potential pressure on leadership.
• Auditors: Kesselman & Kesselman's selection is subject to shareholder ratification, impacting their engagement for FY2026.

Next Steps

• Shareholders will vote on the election of five directors.
• Shareholders will vote on the ratification of Kesselman & Kesselman as independent registered public accounting firm.
• The company will hold its annual meeting of shareholders on June 15, 2026.

Key Dates

Recommendation

The filing is a procedural proxy statement for an annual meeting and does not contain new operational or financial performance data that would warrant a buy or sell recommendation. While the company faces financial challenges (net loss, negative TSR), the election of directors and auditor ratification are standard governance actions. A 'hold' recommendation is appropriate pending more substantive operational or financial updates.

Keywords

Pluri Inc., Annual Meeting, Shareholder Meeting, Proxy Statement, Director Election, Independent Auditor, Corporate Governance, SEC Filing, DEF 14A